N-glycosylation increases the circulatory half-life of human growth hormone

Endocrinology

Volumn 151, Issue 11, 2010, Pages 5326-5336

  Flintegaard, Thomas V ^a,b   Thygesen, Peter ^a   Rahbek Nielsen, Henrik ^a   Levery, Steven B ^b   Kristensen, Claus ^a   Clausen, Henrik ^b   Bolt, Gert ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3N GROWTH HORMONE; GLYCAN DERIVATIVE; HUMAN GROWTH HORMONE; UNCLASSIFIED DRUG; POLYSACCHARIDE;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RAT; SIALYLATION; ANIMAL; CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HALF LIFE TIME; HUMAN; METABOLISM; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HALF-LIFE; HUMAN GROWTH HORMONE; HUMANS; POLYSACCHARIDES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78049511255     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0574     Document Type: Article

References (49)

1. Lanning NJ, Carter-Su C 2006 Recent advances in growth hormone signaling. Rev Endocr Metab Disord 7:225-235 (Pubitemid 46399314)
2. Giustina A, Mazziotti G, Canalis E 2008 Growth hormone, insulinlike growth factors, and the skeleton. Endocr Rev 29:535-559
3. Møller N, Jørgensen JOL 2009 Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30:152-177
4. Cummings DE, Merriam GR 2003 Growth hormone therapy in adults. Annu Rev Med 54:513-533
5. Quigley CA 2007 Growth hormone treatment of non-growth hormone-deficient growth disorders. Endocrinol Metab Clin North Am 36:131-186 (Pubitemid 46335845)
6. Denson LA 2008 Growth hormone therapy in children and adolescents: pharmacokinetic/pharmacodynamic considerations and emerging indications. Expert Opin Drug Metab Toxicol 4:1569-1580
7. MacGillivray MH, Baptista J, Johanson A 1996 Outcome of a fouryear randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. J Clin Endocrinol Metab 81:1806-1809
8. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G, Chang S, Chu H, Mukku V, Canova-Davis E, Somers T, Cronin M, Winkler M, Wells JA 1996 Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271:21969-21977
9. DeFrees S, Wang ZG, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van der Linden EC, Bayer RJ, Tarp MA, Clausen H 2006 GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16:833-843
10. Cox GN, Rosendahl MS, Chlipala EA, Smith DJ, Carlson SJ, Doherty DH 2007 A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats. Endocrinology 148:1590-1597
11. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J 1995 Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312:725-731 (Pubitemid 26005980)
12. LaPolt PS, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJW 1992 Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone antagonists with extended carboxyl-terminal peptides. Endocrinology 131:2514-2520
13. Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ 2002 Albutropin: a growth hormonealbumin fusion protein with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol 456:149-158 (Pubitemid 35351748)
14. Wilkinson IR, Ferrandis E, Artymiuk PJ, Teillot M, Soulard C, Touvay C, Pradhananga SL, Justice S, Wu Z, Leung KC, Strasburger CJ, Sayers JR, Ross RJ 2007 A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist. Nat Med 13:1108-1113 (Pubitemid 47517502)
15. Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, Gillies SD, Folkman J, Javaherian K 2008 Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 14:1487-1493 (Pubitemid 351413933)
16. Kelleher DJ, Kreibich G, Gilmore R 1992 Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kDa protein. Cell 69:55-65
17. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA 2003 Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299
18. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J 2003 Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414-421
19. Perlman S, van den Hazel B, Christiansen J, Gram-Nielsen S, Jeppesen CB, Andersen KV, Halkier T, Okkels S, Schambye HT 2003 Glycosylation of an N-terminal extension prolongs the halflife and increases the in vivo activity of follicle stimulating hormone. J Clin Endocrinol Metab 88:3227-3235
20. Weenen C, Peña JE, Pollak SV, Klein J, Lobel L, Trousdale RK, Palmer S, Lustbader EG, Ogden RT, Lustbader JW 2004 Longacting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with O-linked analogs in female rats. J Clin Endocrinol Metab 89:5204-5212
21. Ceaglio N, Etcheverrigaray M, Kratje R, Oggero M 2008 Novel long-lasting interferon α derivatives designed by glycoengineering. Biochimie (Paris) 90:437-449
22. Sundström M, Lundqvist T, Rödin J, Giebel LB, Milligan D, Norstedt G 1996 Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 Å resolution. J Biol Chem 271:32197-32203
23. Durocher Y, Perret S, Kamen A 2002 High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9
24. Takahashi Y, Shirono H, Arisaka O, Takahashi K, Yagi T, Koga J, Kaji H, Okimura Y, Abe H, Tanaka T, Chihara K 1997 Biological inactive growth hormone caused by amino acid substitution. J Clin Invest 100:1159-1165
25. Behncken SN, Rowlinson SW, Rowland JE, Conway-Campbell BL, Monks TA, Waters MJ 1997 Aspartate 171 is the major primate-specific determinant of human growth hormone. J Biol Chem 272:27077-27083
26. Ray J, Jones BK, Liebhaber SA, Cooke NE 1989 Glycosylated human growth hormone variant. Endocrinology 125:566-568
27. Frankenne F, Scippo ML, Van Beeumen J, Igout A, Hennen G 1990 Identification of placental growth hormone as the growth hormone-V gene expression product. J Clin Endocrinol Metab 71:15-18 (Pubitemid 120020240)
28. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I 2004 Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32:1146-1155 (Pubitemid 39601120)
29. Haffner D, Schaefer F, Girard J, Ritz E, Mehls O 1994 Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J Clin Invest 93:1163-1171 (Pubitemid 24087171)
30. Hansen T, K, Gravholt CH, Ørskov H, Rasmussen MH, Christiansen JS, Jørgensen JO 2002 Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. J Clin Endocrinol Metab 87:4691-4698
31. Webster R, Xie R, Didier E, Finn R, Finnessy J, Edgington A, Walker D 2008 PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humans. Xenobiotica 38:1340-1351
32. Kornfeld R, Kornfeld S 1985 Assembly of asparagine linked oligosaccharides. Annu Rev Biochem 54:631-664
33. Chang RL, Deen WM, Robertson CR, Brenner BM 1975 Permselectivity of the glomerular capillary wall: III. Restricted transport of polyanions. Kidney Int 8:212-218
34. Venkatachalam MA, Rennke HG 1978 The structural and molecular basis of glomerular filtration. Circ Res 43:337-347
35. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D 1979 Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 16:251-270
36. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV 1988 Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 263:15064-15070
37. Ashwell G, Morell AG 1974 The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 41:99-128
38. Elliott S, Pham E, Macdougall IC 2008 Erythropoietins: a common mechanism of action. Exp Hematol 36:1573-1584
39. Egrie JC, Browne JK 2001 Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1):3-10
40. Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S 1995 Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood 86:4097-4104
41. Chitlaru T, Kronman C, Zeevi M, Kam M, Harel A, Ordentlich A, Velan B, Shafferman A 1998 Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem J 336:647-658
42. Gu X, Wang DIC 1998 Improvement of interferon-γ sialylation in Chinese hamster ovary cell culture by feeding of N-acetylmannosamine. Biotechnol Bioeng 58:642-648
43. Fukuta K, Abe R, Yokomatsu T, Kono N, Asanagi M, Omae F, Minowa MT, Takeuchi M, Makino T 2000 Remodeling of sugar chain structures of human interferon-γ. Glycobiology 10:421-430
44. Gawlitzek M, Estacio M, Fürch T, Kiss R 2009 Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells. Biotechnol Bioeng 103:1164-1175
45. Plotnick LP, Thompson RG, Kowarski A, De Lacerda L, Migeon CJ, Blizzard RM 1975 Circadian variation of integrated concentration of growth hormone in children and adults. J Clin Endocrinol Metab 40:240-247
46. Laursen T 2004 Clinical pharmacological aspects of growth hormone administration. Growth Hormone IGF Res 14:16-44
47. Maiter D, Underwood LE, Maes M, Davenport ML, Ketelslegers JM 1988 Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats. Endocrinology 123:1053-1059
48. Isgaard J, Carlsson L, Isaksson OG, Jansson JO 1988 Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology 123:2605-2610
49. Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard A-M, Jørgensen JOL, Christiansen JS 2001 Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 86:1222-1228